Q-Line Biotech claims to have established manufacturing and R&D capabilities in the in-vitro diagnostics (IVD) segment. The company operates four manufacturing facilities, including three in Lucknow and one in Delhi, with installed capacity for manufacturing reagent kits and diagnostic analysers. It also claims to have a dedicated R&D team of 19 scientists and engineers working on product development, reverse engineering, and validation.
The company has developed a diversified product portfolio across multiple diagnostic categories. Its offerings include clinical chemistry reagents, haematology reagents, rapid and Elisa kits, molecular diagnostic products, diagnostic analysers, consumables, and annual maintenance services for diagnostic equipment. Reagents and diagnostic instruments together contributed a major portion of its revenue in recent financial years.
Q-Line Biotech claims to have expanded its manufacturing infrastructure through additional facilities commissioned in 2026. According to the prospectus, the expansion is expected to increase production capacity for clinical chemistry reagents, Rapid/Elisa kits, glucometer devices, and glucometer strips. The company is also developing and manufacturing certain “Make in India” diagnostic analysers and laboratory devices.
The company is ISO 13485:2016 certified for its quality management systems for medical devices at its Lucknow manufacturing facility located at Khasra No. 3105, Amausi, Sarojini Nagar, Lucknow. It also states that its facilities have undergone inspections and audits by regulatory authorities and certification agencies, including CDSCO, State Drug Authorities, Intertek, URS Certification Limited, and certain European regulatory agencies.
Q-Line Biotech claims to have a distribution and service network spread across multiple regions in India. As of March 31, 2026, the company had 283 distributors, 103 sales personnel, and 35 service engineers supporting laboratories, hospitals, institutions, and distributors. The company states that it markets products across around 26 states and Union Territories.
Q-Line Biotech is led by promoters and senior management with experience in the diagnostic and healthcare industry. Promoter and chairman & managing director Saurabh Garg has over 31 years of experience in the healthcare and diagnostics sector, while other senior management personnel oversee areas including manufacturing, R&D, operations, finance, and strategic collaborations.
The company has reported growth in revenue and operating profitability over the last few financial years. Revenue from operations increased from Rs 182.74 crore in FY23 to Rs 203.65 crore in FY24, and then to Rs 313.78 crore in FY25, while EBITDA increased from Rs 32.98 crore in FY23 to Rs 37.62 crore in FY24 and Rs 71.32 crore in FY25. EBITDA margins also improved from 18.05% in FY23 to 22.73% in FY25.
The company’s business is significantly dependent on its distributor network, including group entity POCT Services. The top distributor contributed Rs 151.94 crore (65.37%), Rs 197.48 crore (62.94%), Rs 105.22 crore (51.67%), and Rs 69.26 crore (37.90%) to revenue during the period ended December 31, 2025, in FY25, FY24, and FY23, respectively. Further, the top 10 distributors contributed Rs 187.36 crore (80.61%), Rs 257.79 crore (82.16%), Rs 155.03 crore (76.13%), and Rs 138.25 crore (75.66%) during the same periods. Loss of any of these distributors, failure to renew agreements on favourable terms, or the inability to maintain after-sales support may hurt the company’s business operations and financial condition.
The company is dependent on a limited number of suppliers for the procurement of raw materials and traded diagnostic instruments. For raw materials, the top three suppliers contributed Rs 10.27 crore (22.57%), Rs 6.56 crore (14.41%), and Rs 4.36 crore (9.59%) of total raw material purchases during the period ended December 31, 2025. In the instruments segment, the top supplier alone contributed Rs 12.65 crore (47.21%), Rs 19.71 crore (57.08%), Rs 39.34 crore (61.70%), and Rs 10.87 crore (30.87%) of instrument purchases in the period ended December 31, 2025, FY25, FY24, and FY23, respectively. Any disruption in supplies, increase in procurement costs, supply shortages, or preferential pricing offered to competitors could adversely affect the company’s operations, profitability, and customer servicing capabilities.
The company’s operations are dependent on obtaining, renewing, and maintaining multiple statutory approvals, licenses, registrations, and regulatory clearances across its manufacturing facilities, warehouses, and branch offices. The company has several approvals that are pending, yet to be applied for, or are still held in its previous name, including GST registration, import licences, warehouse licences under the Drugs and Cosmetics Rules, fire safety approvals, trade licences, and R&D recognition certificates. Any delay, suspension, non-renewal, cancellation, or failure to obtain these approvals could result in penalties, regulatory actions, disruption in operations, restrictions on imports, lease termination of certain facilities, or temporary suspension of business activities, which may adversely affect the company’s business and financial condition.
A significant portion of the company’s operations and revenue is concentrated in North India, particularly in Uttar Pradesh. The Northern region contributed Rs 252.62 crore (80.51%), Rs 159.22 crore (78.19%), and Rs 142.30 crore (77.87%) to revenue in FY25, FY24, and FY23, respectively. Further, Uttar Pradesh alone contributed Rs 226.72 crore (72.25%), Rs 134.31 crore (65.95%), and Rs 125.20 crore (68.51%) during the same periods. Any adverse political, economic, social, or regional developments in North India, particularly in Uttar Pradesh, could negatively impact the company’s business operations and financial performance.
The company requires substantial working capital to manage day-to-day operations, including procurement of raw materials, freight expenses, labour costs, and other operational requirements. Its working capital increased from Rs 37.28 crore in FY23 to Rs 120.74 crore in FY25 and stood at Rs 201.66 crore as of December 31, 2025. Any inability to secure sufficient working capital facilities or additional financing on favourable terms could affect the company’s ability to meet customer demand, manage operations efficiently, and support future growth plans.
The company has reported negative cash flows from operating activities in three of the last four reported periods. Net cash flow from operating activities stood at negative Rs 33.11 crore, negative Rs 1.32 crore, and negative Rs 24.18 crore in the period ended December 31, 2025, FY25, and FY24, respectively, compared to a positive cash flow of Rs 24.97 crore in FY23. The negative operating cash flows were mainly due to higher working capital requirements, increased credit periods offered to customers, and higher inventory levels. If the company continues to generate negative operating cash flows, it may face pressure on liquidity, working capital management, and future expansion plans.